Sitravatinib has been investigated in combination with anti-PD-1 in different settings, as neoadjuvant treatment for locally advanced ccRCC (phase II, NCT03680521) with promising data. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.